Welcome to our dedicated page for Airsculpt Technologies SEC filings (Ticker: AIRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AirSculpt Technologies (NASDAQ: AIRS) transforms unwanted fat into sleek contours—but its SEC disclosures can be far less streamlined. From detailed clinic economics to patented plasma technology risks, each filing packs information investors need to gauge growth and litigation exposure.
Stock Titan’s AI makes understanding AirSculpt Technologies SEC documents with AI straightforward. Our system tags every AirSculpt Technologies quarterly earnings report 10-Q filing, surfaces procedure-volume KPIs, and flags liquidity metrics in seconds. Real-time alerts let you follow AirSculpt Technologies insider trading Form 4 transactions the moment executives buy or sell shares, answering the common question, “Is management adding to their position?”
Here’s what you’ll uncover faster than scrolling through EDGAR:
- 10-K annual report simplified: AI pinpoints new-center roll-out costs, malpractice insurance provisions, and competitive landscape discussion.
- 8-K material events explained: immediate summaries of clinical study outcomes, financing updates, or leadership changes.
- Form 4 insider transactions real-time: visual trend charts of executive stock moves.
- Proxy statement executive compensation: see how incentive plans tie to clinic openings and same-store revenue.
Whether you search, “How do I read AirSculpt’s 10-K annual report?” or “Track AirSculpt Technologies executive stock transactions Form 4,” our platform answers instantly. Every filing is updated the moment it hits EDGAR, then distilled into concise language—so you can compare quarter-over-quarter margins, monitor risk factors, and act on insights before the market digests hundreds of pages.
Airsculpt Technologies, Inc. (AIRS)11/14/2025, the director reports beneficial ownership of 375,934 shares of Airsculpt Technologies common stock, $0.001 par value, held in direct form. The filing shows no derivative securities currently reported in Table II and includes a power of attorney authorizing an attorney-in-fact to sign on the reporting person's behalf.
AirSculpt Technologies, Inc. appointed Michael Doyle as a Class III director and the Non-Executive Chairman of the Board, effective November 14, 2025. He will stand for election by stockholders at the company’s 2027 annual meeting. Doyle is an experienced healthcare services executive, currently Managing Partner of Vesey Street Capital Partners and formerly CEO of Surgery Partners, where he led the business for about 15 years and expanded it from 3 to over 175 locations. He has also chaired several physician and dental organizations and previously served on the board of managers of Elite Body Sculpture, the company’s predecessor before its IPO. The board determined that he qualifies as an independent director under Nasdaq rules, and he will not receive compensation for serving as a director and Non-Executive Chairman. The company also filed a press release as an exhibit to this report.
AirSculpt Technologies (AIRS) reported weaker Q3 2025 results. Revenue was $34.99 million, down about 18% year over year as procedure volumes and demand across the aesthetics industry softened. The company posted a net loss of $9.51 million (basic and diluted loss per share of $0.15) versus a $6.04 million loss a year ago.
Results included non-cash charges: a $4.6 million impairment tied to portions of a Salesforce implementation and a $2.3 million impairment from the planned closure of the London facility. Management also accelerated $1.0 million of rent expense related to ceasing use of the London lease on November 15, 2025. Same-center cases fell 20.5% with revenue per case modestly lower.
Cash was $5.41 million at quarter-end, and term debt (net) was $56.91 million at an 8.82% interest rate. During Q2, AirSculpt raised approximately $13.8 million net in an underwritten offering and prepaid $10.0 million on the term loan, while amending covenants to provide near-term flexibility. Management is executing cost reductions estimated at $3.0 million annually and has paused new center openings.
AirSculpt Technologies announced quarterly results and updated 2025 revenue guidance and Adjusted EBITDA guidance via press release, and named Michael Arthur as Chief Financial Officer, effective January 5, 2026.
Arthur’s compensation includes a $400,000 annual base salary, target cash bonus equal to 50% of salary (from fiscal 2026), a $100,000 sign‑on cash bonus, and a $600,000 sign‑on equity grant split between RSUs ($300,000) and PSUs ($300,000). RSUs vest over three years; PSUs vest over three years based on relative total shareholder return with achievement from 0% to 200%. Severance provides nine months’ salary and COBRA contributions, or upon a change in control, a lump sum of salary plus target bonus, 12 months’ COBRA contributions, full RSU acceleration, and PSU conversion as described.
AirSculpt Technologies (AIRS) announced a leadership change. On November 4, 2025, Dr. Aaron Rollins resigned as executive chairman and as a member of the board of directors, effective the same day.
The company stated that Dr. Rollins’ resignation was not due to any disagreements with the company, its management, or the board on matters related to operations, policies, or practices. The filing lists no additional board or management changes or interim appointments.
AirSculpt Technologies (AIRS) reported an insider equity event by its Chief Executive Officer and director. On 10/27/2025, the first performance milestone in a previously granted award was achieved, triggering the vesting and acquisition of 56,097 shares of common stock via performance stock units (Transaction Code M).
The CEO was originally granted 220,386 PSUs on 01/07/2025 that vest in four tranches tied to stock price goals. The first goal was met when the 60‑day average price reached $7.56 per share, resulting in this vesting. Following the transaction, the reporting person beneficially owned 520,976 common shares, with 164,289 PSUs remaining outstanding.
AirSculpt Technologies, Inc. Schedule 13G/A discloses that a group led by Vesey Street holds a large, concentrated position in the company’s common stock (CUSIP 009496100). The filing reports that Adam T. Feinstein and affiliated entities together hold 30,324,180 shares, or 48.6% of the outstanding common stock. Ownership is allocated across entities: VSCP EBS Aggregator, L.P. (14,038,819 shares, 22.5%), Vesey Street Capital Partners Healthcare Fund-A, L.P. (4,523,899 shares, 7.2%), and EBS Aggregator Blocker Holdings, LLC (11,761,462 shares, 18.8%).
The reporting persons state they possess shared voting and dispositive power over these shares while asserting no sole voting or dispositive power. The percentage calculations are stated to be based on 62,436,670 shares outstanding as of July 31, 2025, per the issuer’s unaudited condensed consolidated financial statements. The filing explains Mr. Feinstein’s management roles through the Vesey Street organizational structure and notes that each reporting person disclaims beneficial ownership beyond its pecuniary interest.
AirSculpt Technologies (AIRS) Q2-25 10-Q highlights:
- Revenue: $44.0 m, -14% YoY; H1-25 revenue $83.4 m, -15% YoY.
- Case volume: 3,392 for the quarter (-14%); revenue per case stable at ~$12.9k.
- Profitability: Adj. EBITDA $5.8 m (13.3% margin vs. 13.5% LY); GAAP net loss $(0.6) m vs. $(3.2) m LY. H1 net loss $(3.4) m.
- Cost actions: Advertising down $3.7 m; $3 m annual overhead cuts; de-novo expansion paused.
- Capital & liquidity: Cash $8.2 m; term-loan $58.8 m (rate 7.8%); leverage covenant amended in Mar-25; $10 m debt pre-payment on 13-Jun-25 funded by $14 m follow-on equity offering (3.6 m shares at $3.80).
- ATM program: 0.12 m shares sold YTD for $0.3 m.
- Balance sheet: Total assets $198.4 m; stockholders’ equity $91.2 m; net debt ~$50.6 m.
- Guidance/strategy: Management focusing on marketing ROI, sales training, new financing options, product innovation and standalone skin-tightening; aims to stabilize same-center performance amid industry softness.
Key risks include declining demand, leverage (LT debt/Adj. EBITDA ≈ 5.0x), tighter covenants, and rising interest margin from July 2025.
FAQ
What is the current stock price of Airsculpt Technologies (AIRS)?
What is the market cap of Airsculpt Technologies (AIRS)?
